PaulB.EckburgMD
Infectious Disease • Stanford, CAInfectious Diseases at Stanford University and Anti-Infective Drug Development in Industry
Dr. Eckburg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Stanford, CA 94305Phone+1 650-723-4000
Education & Training
Stanford Health Care2004
Stanford Health Care-Sponsored Stanford UniversityFellowship, Infectious Disease, 2000 - 2002- Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1996 - 1999
- Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 1996 - 1997
Rush Medical College of Rush University Medical CenterClass of 1996
Certifications & Licensure
CA State Medical License 1997 - 2025
HI State Medical License 1999 - 1999
Clinical Trials
- Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections Start of enrollment: 2007 Mar 01
- Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections Start of enrollment: 2007 Feb 01
- Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia Start of enrollment: 2007 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 7 citationsOmadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia.Antoni Torres, Lynne Garrity-Ryan, Courtney Kirsch, Judith N. Steenbergen, Paul B. Eckburg
International Journal of Infectious Diseases. 2021-01-20 - 78 citationsFosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase...Keith S Kaye, Louis B. Rice, Aaron Dane, Viktor Stus, Olexiy S. Sagan
Clinical Infectious Diseases. 2019-11-27 - 58 citationsOnce-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, ...William O'Riordan, Carrie Cardenas, Elliot Shin, Alissa Sirbu, Lynne Garrity-Ryan
The Lancet. Infectious Diseases. 2019-10-01
Press Mentions
Recida Therapeutics Raises $8.5M in Series AFebruary 9th, 2019
Frazier Healthcare Partners Launches Recida Therapeutics to Develop Novel Therapeutics for Serious Antibiotic-Resistant InfectionsFebruary 6th, 2019- UTILITY Receives Qualified Infectious Disease Product Designation from the U.S. FDAMay 21st, 2018
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
